Biofilm Antibiotic Tolerance and Resistance: A Review of the Potential and Limits of Next-Generation Combination Therapies
How Biofilms Survive Antibiotics: Tolerance Versus Resistance
Biofilms create conditions that favor survival during antibiotic exposure through structures that impede drug penetration and the low metabolic activity of bacteria. A review published in Frontiers in Microbiology summarizes these survival mechanisms and examines the potential and limitations of treatment strategies including nanocarriers, antimicrobial peptides, phages, and gene-targeting tools. A central theme is the potential to combine approaches that act on different targets.
A biofilm is a community of microorganisms attached to a surface and surrounded by extracellular polymeric substances (EPS) that they produce. EPS includes extracellular DNA, polysaccharides, and proteins. While this structure impedes antibiotic movement and action, slowly growing or metabolically less active bacteria within the biofilm may survive drug exposure.
The review distinguishes antibiotic tolerance in this setting from genetic resistance. Tolerance is a reversible, non-genetic state that allows bacteria to withstand temporary antibiotic exposure without an increase in the minimum inhibitory concentration. Resistance is a heritable ability to grow at drug concentrations that would inhibit the growth of or kill susceptible strains. Biofilms mainly increase tolerance, but surviving bacteria and horizontal gene transfer within the community can create conditions that favor the evolution and spread of resistance over time.
Treatment Candidates Targeting Barriers, Cell Walls, and Signaling
The approaches covered in the review differ in their targets and mechanisms. Nanocarriers are being studied as a means of delivering antibiotics and other agents to biofilms. Antimicrobial peptides (AMPs) are described as candidates that act on cell membranes or inhibit biofilm formation, but degradation in the body, rapid excretion, reduced activity in biological fluids, and toxicity at high concentrations were identified as factors limiting their use.
Bacteriophages, viruses that infect bacteria, and phage-derived enzymes are also considered. Depolymerases break down EPS to facilitate drug access, while lysins degrade peptidoglycan in the bacterial cell wall. These approaches target, respectively, the extracellular polymer barrier and the bacterial cell wall itself.
The review also discusses inhibiting quorum sensing, the exchange of signals among bacteria according to population density, and reducing the expression of related genes with CRISPR interference (CRISPRi). In a cited prior study, CRISPRi targeting the luxS gene in clinical Escherichia coli isolates suppressed biofilm formation by about 50%. This figure describes inhibition of biofilm formation, not treatment success in patients. The provided review text does not specify the number of strains or culture conditions for that experiment, making it difficult to generalize the result.
Challenges in Translating Combination Effects to the Clinic
Combinations such as nanoparticles with antibiotics, quorum-sensing inhibitors with antibiotics, and phages with enzymes were discussed mainly on the basis of in vitro and animal-model evidence. The review also presents case-based clinical reports of phage–antibiotic combinations. However, the review itself did not develop a single treatment combining all these platforms or establish superiority in a comparative clinical trial.
Combination therapy is not always advantageous. Phage replication requires bacterial metabolic activity, so bacteriostatic antibiotics that suppress bacterial growth could interfere with phage replication. Bacteria may also evade quorum-sensing inhibition by altering signaling pathways or activating compensatory pathways.
At actual infection sites, oxygen and nutrient conditions and microbial composition are more complex than in laboratory models, so in vitro effects may not be reproduced in vivo. Delivery efficiency, toxicity, stability during manufacturing, consistency between production batches, and regulatory validation were also identified as challenges for clinical translation. The review outlines directions for developing combination candidates; it does not demonstrate improved patient cure rates or complete prevention of new resistance.
Source: Original review in Frontiers in Microbiology.
Biofilm mediated antimicrobial resistance (AMR) has become a critical global health and economic challenge, affecting both community and healthcare settings. Microbial Biofilms significantly enhance the antibiotic tolerance and cause the persistent and device-associated infections via limited drug penetration, degradation of antibiotics, and assist horizontal gene transfer. Biofilm-mediated antimicrobial resistance remains a major obstacle to treating infectious diseases today. Biofilms can boost antibiotic tolerance by up to 1,000 times and lead to chronic, persistent, and device-associated infections. The lack of FDA-approved anti-biofilm drugs highlights the urgent need for new therapeutic strategies and mechanistic insights. Redefining the treatment landscape and improving outcomes for resistant infections could be achieved through a multi-platform therapeutic approach. This review summarizes recent developments in our knowledge of how biofilms contribute to antibiotic resistance and highlights new therapeutic strategies, such as nanotechnology, antimicrobial peptides, bacteriophage-derived enzymes, quorum-sensing inhibitors, CRISPR-based tools, microbiome engineering, and AI-driven drug discovery.
This review summarizes evidence that can help distinguish the structural barriers of biofilms, the low metabolic activity of bacteria, and genetic resistance when assessing treatment candidates for chronic wounds or medical device-associated infections. For example, developing a phage–antibiotic combination would start by checking whether the phage can infect the target strain and whether the antibiotic interferes with phage replication. A reduction in biofilm in vitro alone does not justify expecting the same effect in patients. Bacterial clearance and regrowth, toxicity, and delivery stability need to be assessed in models that reflect the infection site, and clinical evidence must be built. Determining the conditions under which each combination offers benefits or poses risks can guide candidate selection and formulation development.